Benitec BioPharma's Gene Therapy Shows Promising Results in Oculopharyngeal Muscular Dystrophy Trial
核心洞察
Benitec BioPharma reports a 35% reduction in total score on the Sydney Swallow Questionnaire in the first patient treated with their gene therapy for oculopharyngeal muscular dystrophy (搜索) (OPMD).
Therapeutic RNA editing has been clinically demonstrated in humans for the first time, according to the company's press release.
A phase 1 clinical trial initially cleared for lupus nephritis (搜索) has expanded to include more eligible indications following IND amendments.
Benitec BioPharma has announced promising initial results from its gene therapy trial for oculopharyngeal muscular dystrophy (搜索) (OPMD). The first patient treated showed a clinically meaningful 35% reduction in the total score on the Sydney Swallow Questionnaire, indicating an improvement in swallowing function.
RNA Editing Breakthrough
The company reports that this marks the first time therapeutic RNA editing has been clinically demonstrated in humans. This achievement represents a significant milestone in the development of RNA-based therapies for a range of genetic diseases.
Bristol Myers Squibb's Cell Therapy Advances
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb (搜索)’s Cell Therapy Organization, discussed the company’s planned presentation at ACR Convergence 2024, highlighting ongoing advancements in cell therapy research.
Gene Therapy for Ocular Diseases
In a separate study, among 7 patients' eyes treated with a high dose of a gene therapy, the response rate was 57% (4/7 eyes), suggesting potential efficacy in treating certain ocular diseases.
Trial Expansion for Lupus Nephritis
A phase 1 clinical trial, initially cleared for the recruitment of patients with lupus nephritis (搜索), has been expanded to include more eligible indications following IND amendments, broadening the scope of the study and potentially benefiting a larger patient population.